203 related articles for article (PubMed ID: 28870519)
1. Sigma-1 receptor knockout increases α-synuclein aggregation and phosphorylation with loss of dopaminergic neurons in substantia nigra.
Hong J; Wang L; Zhang T; Zhang B; Chen L
Neurobiol Aging; 2017 Nov; 59():171-183. PubMed ID: 28870519
[TBL] [Abstract][Full Text] [Related]
2. Seipin deficiency in mice causes loss of dopaminergic neurons via aggregation and phosphorylation of α-synuclein and neuroinflammation.
Wang L; Hong J; Wu Y; Liu G; Yu W; Chen L
Cell Death Dis; 2018 May; 9(5):440. PubMed ID: 29670081
[TBL] [Abstract][Full Text] [Related]
3. Sigma-1 receptor deficiency reduces MPTP-induced parkinsonism and death of dopaminergic neurons.
Hong J; Sha S; Zhou L; Wang C; Yin J; Chen L
Cell Death Dis; 2015 Jul; 6(7):e1832. PubMed ID: 26203861
[TBL] [Abstract][Full Text] [Related]
4. 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model.
Underwood R; Gannon M; Pathak A; Kapa N; Chandra S; Klop A; Yacoubian TA
Acta Neuropathol Commun; 2021 Jan; 9(1):13. PubMed ID: 33413679
[TBL] [Abstract][Full Text] [Related]
5. Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.
Maki RA; Holzer M; Motamedchaboki K; Malle E; Masliah E; Marsche G; Reynolds WF
Free Radic Biol Med; 2019 Sep; 141():115-140. PubMed ID: 31175983
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of MPTP-induced α-synuclein oligomerization by fatty acid-binding protein 3 ligand in MPTP-treated mice.
Matsuo K; Cheng A; Yabuki Y; Takahata I; Miyachi H; Fukunaga K
Neuropharmacology; 2019 May; 150():164-174. PubMed ID: 30930168
[TBL] [Abstract][Full Text] [Related]
7. Sigma-1 (σ₁) receptor deficiency reduces β-amyloid(25-35)-induced hippocampal neuronal cell death and cognitive deficits through suppressing phosphorylation of the NMDA receptor NR2B.
Yin J; Sha S; Chen T; Wang C; Hong J; Jie P; Zhou R; Li L; Sokabe M; Chen L
Neuropharmacology; 2015 Feb; 89():215-24. PubMed ID: 25286118
[TBL] [Abstract][Full Text] [Related]
8. Modeling Parkinson's Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein Oligomers.
Boi L; Pisanu A; Palmas MF; Fusco G; Carboni E; Casu MA; Satta V; Scherma M; Janda E; Mocci I; Mulas G; Ena A; Spiga S; Fadda P; De Simone A; Carta AR
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198335
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive bioluminescence imaging of α-synuclein oligomerization in mouse brain using split firefly luciferase reporters.
Aelvoet SA; Ibrahimi A; Macchi F; Gijsbers R; Van den Haute C; Debyser Z; Baekelandt V
J Neurosci; 2014 Dec; 34(49):16518-32. PubMed ID: 25471588
[TBL] [Abstract][Full Text] [Related]
10. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
Coune PG; Bensadoun JC; Aebischer P; Schneider BL
J Parkinsons Dis; 2011; 1(4):373-87. PubMed ID: 23939344
[TBL] [Abstract][Full Text] [Related]
11. In parkinsonian substantia nigra, alpha-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity.
Shamoto-Nagai M; Maruyama W; Hashizume Y; Yoshida M; Osawa T; Riederer P; Naoi M
J Neural Transm (Vienna); 2007; 114(12):1559-67. PubMed ID: 17690948
[TBL] [Abstract][Full Text] [Related]
12. Bimolecular Fluorescence Complementation of Alpha-synuclein Demonstrates its Oligomerization with Dopaminergic Phenotype in Mice.
Cai W; Feng D; Schwarzschild MA; McLean PJ; Chen X
EBioMedicine; 2018 Mar; 29():13-22. PubMed ID: 29433982
[TBL] [Abstract][Full Text] [Related]
13. A30P α-synuclein impairs dopaminergic fiber regeneration and interacts with L-DOPA replacement in MPTP-treated mice.
Szego ÉM; Gerhardt E; Kermer P; Schulz JB
Neurobiol Dis; 2012 Jan; 45(1):591-600. PubMed ID: 22001606
[TBL] [Abstract][Full Text] [Related]
14. Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology.
Ulusoy A; Febbraro F; Jensen PH; Kirik D; Romero-Ramos M
Eur J Neurosci; 2010 Aug; 32(3):409-22. PubMed ID: 20704592
[TBL] [Abstract][Full Text] [Related]
15. Cre-inducible Adeno Associated Virus-mediated Expression of P301L Mutant Tau Causes Motor Deficits and Neuronal Degeneration in the Substantia Nigra.
You Y; Botros MB; Enoo AAV; Bockmiller A; Herron S; Delpech JC; Ikezu T
Neuroscience; 2019 Dec; 422():65-74. PubMed ID: 31689387
[TBL] [Abstract][Full Text] [Related]
16. The new line of genetically modified mice with constitutive knockout of the gene alpha synuclein to study pathogenetic aspects of differential loss of dopaminergic neurons .
Tarasova TV; Ustyugov AA; Ninkina NN; Skvortsova VI
Patol Fiziol Eksp Ter; 2016; 60(3):4-9. PubMed ID: 29243900
[TBL] [Abstract][Full Text] [Related]
17. Alpha-synuclein-induced neurodegeneration is exacerbated in PINK1 knockout mice.
Oliveras-Salvá M; Macchi F; Coessens V; Deleersnijder A; Gérard M; Van der Perren A; Van den Haute C; Baekelandt V
Neurobiol Aging; 2014 Nov; 35(11):2625-2636. PubMed ID: 25037286
[TBL] [Abstract][Full Text] [Related]
18. Oxidative stress-induced posttranslational modifications of alpha-synuclein: specific modification of alpha-synuclein by 4-hydroxy-2-nonenal increases dopaminergic toxicity.
Xiang W; Schlachetzki JC; Helling S; Bussmann JC; Berlinghof M; Schäffer TE; Marcus K; Winkler J; Klucken J; Becker CM
Mol Cell Neurosci; 2013 May; 54():71-83. PubMed ID: 23369945
[TBL] [Abstract][Full Text] [Related]
19. Suppression of α-synuclein propagation after intrastriatal injection in FABP3 null mice.
Matsuo K; Kawahata I; Melki R; Bousset L; Owada Y; Fukunaga K
Brain Res; 2021 Jun; 1760():147383. PubMed ID: 33636166
[TBL] [Abstract][Full Text] [Related]
20. The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson's disease.
Jimenez-Ferrer I; Bäckström F; Dueñas-Rey A; Jewett M; Boza-Serrano A; Luk KC; Deierborg T; Swanberg M
Brain Behav Immun; 2021 Jan; 91():369-382. PubMed ID: 33223048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
